GLP-1 and Vitamin D Levels: Deficiency Risk

    By Trimi Medical Team10 min read

    Vitamin D deficiency is already common in the general population and is even more prevalent in obese individuals. GLP-1 treatment introduces additional considerations: reduced caloric intake decreases dietary vitamin D sources, and fat loss releases stored vitamin D but may not compensate long-term. Monitoring and supplementation are important parts of a complete GLP-1 treatment plan.

    Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for supplementation recommendations.

    Vitamin D Levels

    • Optimal: 40-60 ng/mL
    • Sufficient: 30-39 ng/mL
    • Insufficient: 20-29 ng/mL
    • Deficient: Below 20 ng/mL

    Why Obese Patients Start Low

    Vitamin D is fat-soluble and gets sequestered in adipose tissue. Obese individuals have more fat tissue that "traps" vitamin D, making less available in the bloodstream. Studies show that obese individuals have vitamin D levels 20-30% lower than normal-weight counterparts even with similar sun exposure and dietary intake.

    GLP-1 Treatment Effects

    During GLP-1 treatment, vitamin D levels can be affected in several ways:

    • Reduced dietary intake: Eating less means fewer dietary sources of vitamin D (fatty fish, fortified dairy, eggs)
    • Fat loss release: As fat tissue is broken down, stored vitamin D is released, which can temporarily improve levels
    • Reduced fat absorption: GLP-1 medications alter fat digestion, potentially reducing fat-soluble vitamin absorption
    • Net effect: Levels may initially improve from fat loss release, then decline if supplementation is not maintained

    Why Vitamin D Matters During Weight Loss

    • Bone health: Vitamin D is essential for calcium absorption; deficiency increases fracture risk, especially during rapid weight loss
    • Muscle function: Vitamin D deficiency impairs muscle strength and recovery, which matters when trying to preserve muscle mass on GLP-1
    • Immune function: Vitamin D supports immune regulation
    • Mood: Low vitamin D is associated with depression and fatigue
    • Metabolic health: Adequate vitamin D supports insulin sensitivity

    Supplementation Guidelines

    Most GLP-1 patients benefit from vitamin D supplementation:

    • General recommendation: 2,000-4,000 IU vitamin D3 daily
    • If deficient (below 20 ng/mL): 5,000-10,000 IU daily for 8-12 weeks, then recheck
    • Take with fat: Vitamin D is fat-soluble; take with a meal containing some fat for best absorption
    • Vitamin D3 preferred: D3 (cholecalciferol) is more effective at raising blood levels than D2

    Monitoring Schedule

    • Baseline: 25-hydroxyvitamin D before starting GLP-1
    • 6 months: Recheck to assess supplementation adequacy
    • Annually: Ongoing monitoring during treatment

    Getting Started

    Vitamin D monitoring should be part of your GLP-1 treatment plan. Visit Trimi's treatment options page. Compounded semaglutide is $99/month and tirzepatide is $125/month.

    Frequently Asked Questions

    Should I take vitamin D on GLP-1?

    Most patients benefit from vitamin D supplementation during GLP-1 treatment, as reduced caloric intake decreases dietary vitamin D sources. A typical dose is 2,000-4,000 IU of vitamin D3 daily, adjusted based on blood levels.

    Will losing weight fix my vitamin D deficiency?

    Paradoxically, levels may temporarily improve as fat loss releases stored vitamin D. However, long-term deficiency risk increases with reduced dietary intake. Supplementation is typically needed regardless of weight loss.

    Can low vitamin D affect my weight loss?

    Severe vitamin D deficiency is associated with fatigue, muscle weakness, and impaired metabolism, all of which can indirectly affect weight loss progress. Maintaining adequate levels supports optimal treatment outcomes.

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    Related Reading